Sundaram Preethi, Chief Strategy Officer at Catalyst Pharmaceuticals ($CPRX), sold shares on the open market twice in the last year, totaling about $104 thousand. Her most recent sale occurred on June 11, 2025. These sales rank her 9,523rd among 11,678 insiders by value sold, well below the average of $8.6 million across about six transactions per insider. She made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 29, 2025 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Restricted Stock Units | 6667 | $0.00 | 798,437.0000 | 127,201,954 | 0.83% | 0.01% |
| Dec. 29, 2025 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | F | Common Stock, par value $0.001 per share | 2369 | $0.00 | 54,804.0000 | 127,201,954 | 4.14% | 0.00% |
| Dec. 29, 2025 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Common Stock, par value $0.001 per share | 6667 | $0.00 | 57,173.0000 | 127,201,954 | 13.20% | 0.01% |
| Dec. 8, 2025 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Common Stock, par value $0.001 per share | 6855 | $0.00 | 52,175.0000 | 127,201,954 | 15.13% | 0.01% |
| Dec. 8, 2025 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Restricted Stock Units | 6855 | $0.00 | 805,104.0000 | 127,201,954 | 0.84% | 0.01% |
| Dec. 8, 2025 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | F | Common Stock, par value $0.001 per share | 1669 | $0.00 | 50,506.0000 | 127,201,954 | 3.20% | 0.00% |
| Nov. 21, 2025 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | F | Common Stock, par value $0.001 per share | 1364 | $0.00 | 45,320.0000 | 127,201,954 | 2.92% | 0.00% |
| Nov. 21, 2025 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Common Stock, par value $0.001 per share | 5603 | $0.00 | 46,684.0000 | 127,201,954 | 13.64% | 0.00% |
| Nov. 20, 2025 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | A | Options to purchase common stock | 106873 | $0.00 | 785,305.0000 | 127,201,954 | 15.75% | 0.08% |
| Nov. 20, 2025 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | A | Restricted Stock Units | 32257 | $0.00 | 817,562.0000 | 127,201,954 | 4.11% | 0.03% |
| Nov. 21, 2025 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Restricted Stock Units | 5603 | $0.00 | 811,959.0000 | 127,201,954 | 0.69% | 0.00% |
| June 10, 2025 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | S | Common Stock, par value $0.001 per share | 2324 | $26.41 | 42,681.0000 | 124,943,603 | 5.16% | 0.00% |
| June 11, 2025 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | S | Common Stock, par value $0.001 per share | 1600 | $26.42 | 41,081.0000 | 124,943,603 | 3.75% | 0.00% |
| Feb. 14, 2025 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Restricted Stock Units | 16667 | $0.00 | 678,432.0000 | 124,943,603 | 2.40% | 0.01% |
| Feb. 14, 2025 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Common Stock, par value $0.001 per share | 16667 | $0.00 | 50,970.0000 | 124,943,603 | 48.59% | 0.01% |
| Feb. 14, 2025 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | F | Common Stock, par value $0.001 per share | 5965 | $0.00 | 45,005.0000 | 124,943,603 | 11.70% | 0.00% |
| Dec. 27, 2024 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Restricted Stock Units | 6667 | $0.00 | 695,099.0000 | 125,407,279 | 0.95% | 0.01% |
| Dec. 27, 2024 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | F | Common Stock, par value $0.001 per share | 2345 | $0.00 | 34,303.0000 | 125,407,279 | 6.40% | 0.00% |
| Dec. 27, 2024 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Common Stock, par value $0.001 per share | 6667 | $0.00 | 36,648.0000 | 125,407,279 | 22.24% | 0.01% |
| Dec. 9, 2024 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | F | Common Stock, par value $0.001 per share | 2415 | $0.00 | 29,981.0000 | 125,407,279 | 7.45% | 0.00% |
| Dec. 9, 2024 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Restricted Stock Units | 6855 | $0.00 | 701,766.0000 | 125,407,279 | 0.97% | 0.01% |
| Dec. 9, 2024 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Common Stock, par value $0.001 per share | 6855 | $0.00 | 32,396.0000 | 125,407,279 | 26.84% | 0.01% |
| Nov. 21, 2024 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | A | Options to purchase common stock | 137553 | $0.00 | 691,812.0000 | 125,407,279 | 24.82% | 0.11% |
| Nov. 21, 2024 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | A | Options to purchase common stock | 16809 | $0.00 | 708,621.0000 | 125,407,279 | 2.43% | 0.01% |
| Feb. 15, 2024 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Restricted Stock Units | 16667 | $0.00 | 554,259.0000 | 113,753,154 | 2.92% | 0.01% |
| Feb. 15, 2024 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Common Stock, par value $0.001 per share | 16667 | $0.00 | 31,566.0000 | 113,753,154 | 111.87% | 0.01% |
| Feb. 15, 2024 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | F | Common Stock, par value $0.001 per share | 6025 | $0.00 | 25,541.0000 | 113,753,154 | 19.09% | 0.01% |
| Dec. 27, 2023 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Restricted Stock Units | 6666 | $0.00 | 570,926.0000 | 111,375,631 | 1.15% | 0.01% |
| Dec. 27, 2023 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | F | Common Stock, par value $0.001 per share | 2409 | $0.00 | 14,899.0000 | 111,375,631 | 13.92% | 0.00% |
| Dec. 27, 2023 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Common Stock, par value $0.001 per share | 6666 | $0.00 | 17,308.0000 | 111,375,631 | 62.64% | 0.01% |
| Dec. 8, 2023 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | A | Restricted Stock Units | 20565 | $0.00 | 577,592.0000 | 111,375,631 | 3.69% | 0.02% |
| Dec. 8, 2023 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | A | Options to purchase common stock | 143193 | $0.00 | 557,027.0000 | 111,375,631 | 34.60% | 0.13% |
| Feb. 15, 2023 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Common Stock, par value $0.001 per share | 16666 | $0.00 | 16,666.0000 | 111,375,631 | 9999.99% | 0.01% |
| Feb. 15, 2023 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | F | Common Stock, par value $0.001 per share | 6024 | $0.00 | 10,642.0000 | 111,375,631 | 36.15% | 0.01% |
| Feb. 15, 2023 | CATALYST PHARMACEUTICALS, INC. | $CPRX | Sundaram Preethi | Chief Strategy Officer | M | Restricted Stock Units | 16666 | $0.00 | 413,834.0000 | 111,375,631 | 4.20% | 0.01% |